Neo Ivy Capital Management’s Amedisys AMED Stock Holding History

Neo Ivy Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-426	Closed	-$44K	–	379
2022 Q2	$44K	Buy	+426	New	+$54.4K	0.12%	251

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Neo Ivy Capital Management's AMED Position: Q3 2022 in Review

Neo Ivy Capital Management sold out of Amedisys (AMED) in Q3 2022, closing a stake of 426 shares — an estimated $44K sold.

Neo Ivy Capital Management first reported a position in AMED in Q2 2022 and held it in 1 quarter. The position peaked at $44K in Q2 2022. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2022.

Neo Ivy Capital Management reported no remaining Amedisys position as of Q3 2022 after selling out during the quarter.
Neo Ivy Capital Management sold 426 Amedisys shares in Q3 2022, an estimated $44K.
Neo Ivy Capital Management first reported a position in Amedisys in Q2 2022 and held it in 1 quarter.
Neo Ivy Capital Management's Amedisys position peaked at $44K in Q2 2022.
286 funds tracked by Wall St. Rank held Amedisys as of Q3 2022.

Based on Neo Ivy Capital Management's 13F filing for Q3 2022, filed 16 Nov 2022.